Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CYPS317
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Yorkville
Deal Size : $25.0 million
Deal Type : Financing
FibroBiologics Announces $25 Million Financing
Details : The financing is intended to support the clinical development of CYPS317, currently being evaluated for the treatment of psoriasis.
Product Name : CYPS317
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 23, 2024
Lead Product(s) : CYPS317
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Yorkville
Deal Size : $25.0 million
Deal Type : Financing